Takeda Financial Statements From 2010 to 2026

TAK Stock  USD 17.49  0.26  1.51%   
Analyzing historical trends in various income statement and balance sheet accounts from Takeda Pharmaceutical's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Takeda Pharmaceutical's valuation are summarized below:
Gross Profit
2.9 T
Profit Margin
0.0253
Market Capitalization
54.4 B
Enterprise Value Revenue
2.7396
Revenue
4.5 T
There are currently one hundred twenty fundamental trend indicators for Takeda Pharmaceutical Co that can be evaluated and compared over time across competition. We recommend to double-check Takeda Pharmaceutical's current fundamental drivers against the all of the trends between 2010 and 2026.

Takeda Pharmaceutical Total Revenue

5.53 Trillion

Check Takeda Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Takeda Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 919.4 B, Interest Expense of 165.8 B or Selling General Administrative of 805.7 B, as well as many indicators such as Price To Sales Ratio of 1.66, Dividend Yield of 0.0252 or PTB Ratio of 1.1. Takeda financial statements analysis is a perfect complement when working with Takeda Pharmaceutical Valuation or Volatility modules.
  
Build AI portfolio with Takeda Stock
Check out the analysis of Takeda Pharmaceutical Correlation against competitors.

Takeda Pharmaceutical Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets17.2 T16.4 T9.4 T
Slightly volatile
Common Stock Shares Outstanding2.5 B3.7 B2.4 B
Slightly volatile
Short and Long Term Debt Total5.5 T5.2 T2.9 T
Slightly volatile
Other Current LiabilitiesT1.9 TT
Slightly volatile
Total Current LiabilitiesT2.9 T1.7 T
Slightly volatile
Total Stockholder Equity8.4 TT4.3 T
Slightly volatile
Property Plant And Equipment Net2.4 T2.3 T1.2 T
Slightly volatile
Current Deferred Revenue120.1 B126.4 B339.3 B
Very volatile
Retained Earnings1.4 T1.1 T1.5 T
Slightly volatile
Accounts Payable182.6 B354.7 B222.5 B
Slightly volatile
Cash576.4 B346.6 B542.2 B
Very volatile
Non Current Assets Total14.2 T13.5 T7.4 T
Slightly volatile
Non Currrent Assets Other60.1 B63.3 B89.1 B
Slightly volatile
Cash And Short Term Investments705.6 B365 B610.6 B
Pretty Stable
Net Receivables507.6 B834 B575.4 B
Slightly volatile
Common Stock Total EquityT1.9 T969.7 B
Slightly volatile
Short Term Investments17.5 B18.4 B46.8 B
Slightly volatile
Liabilities And Stockholders Equity17.2 T16.4 T9.4 T
Slightly volatile
Non Current Liabilities Total5.8 T5.5 T3.4 T
Slightly volatile
Inventory1.5 T1.4 T668.9 B
Slightly volatile
Other Current Assets223.3 B155.7 B176.4 B
Pretty Stable
Total Liabilities8.8 T8.4 T5.1 T
Slightly volatile
Property Plant And Equipment GrossT3.8 T1.6 T
Slightly volatile
Total Current Assets2.1 T2.9 TT
Slightly volatile
Short Term Debt662.8 B631.3 B331.5 B
Slightly volatile
Intangible Assets4.4 T4.2 T2.6 T
Slightly volatile
Common StockT1.9 T974.1 B
Slightly volatile
Good Will6.4 T6.1 TT
Slightly volatile
Other Liabilities713.1 B625.7 B486.8 B
Slightly volatile
Property Plant Equipment1.3 T2.3 T976.9 B
Slightly volatile
Cash And Equivalents350.8 B268.8 B303.6 B
Pretty Stable
Net Invested Capital10.7 T13.2 T7.2 T
Slightly volatile
Capital Stock1.8 T1.9 T1.7 T
Slightly volatile

Takeda Pharmaceutical Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization919.4 B875.6 B426.6 B
Slightly volatile
Interest Expense165.8 B157.9 B61.1 B
Slightly volatile
Selling General Administrative805.7 B1.3 T792.1 B
Slightly volatile
Total Revenue5.5 T5.3 T2.9 T
Slightly volatile
Gross Profit3.6 T3.5 T1.9 T
Slightly volatile
Other Operating Expenses5.1 T4.9 T2.6 T
Slightly volatile
EBITDA1.5 T1.4 T718.9 B
Slightly volatile
Cost Of Revenue1.9 T1.8 T926.3 B
Slightly volatile
Total Operating Expenses3.2 T3.1 T1.7 T
Slightly volatile
Selling And Marketing Expenses126.6 B130.2 B121.6 B
Slightly volatile
Research Development505 B839.8 B468.3 B
Slightly volatile
Interest Income219.7 B209.3 B56.3 B
Slightly volatile
Reconciled Depreciation596 B875.6 B416.6 B
Slightly volatile

Takeda Pharmaceutical Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow607.9 B412 B565.5 B
Pretty Stable
Depreciation919.4 B875.6 B436 B
Slightly volatile
Dividends Paid365.3 B347.9 B211.5 B
Slightly volatile
Capital Expenditures141.5 B230.9 B186.3 B
Slightly volatile
Total Cash From Operating Activities1.3 T1.2 T598.5 B
Slightly volatile
End Period Cash Flow614 B346.6 B536.5 B
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.661.752.5774
Slightly volatile
Dividend Yield0.02520.03910.0376
Slightly volatile
PTB Ratio1.11.161.7853
Slightly volatile
Days Sales Outstanding94.1966.4585.9809
Slightly volatile
Book Value Per Share2.2 KK3.2 K
Slightly volatile
Operating Cash Flow Per Share277549385
Slightly volatile
Capex To Depreciation0.290.30.3186
Slightly volatile
PB Ratio1.11.161.7853
Slightly volatile
EV To Sales3.932.973.268
Pretty Stable
Inventory Turnover2.712.012.2991
Slightly volatile
Days Of Inventory On Hand131188178
Slightly volatile
Payables Turnover3.986.25.3405
Slightly volatile
Sales General And Administrative To Revenue0.460.320.3259
Slightly volatile
Research And Ddevelopement To Revenue0.20.180.1744
Pretty Stable
Capex To Revenue0.03060.03940.0368
Very volatile
Cash Per Share266280538
Slightly volatile
POCF Ratio7.918.3223.4736
Slightly volatile
Interest Coverage3.673.8625.3705
Slightly volatile
Capex To Operating Cash Flow0.210.190.3106
Pretty Stable
Days Payables Outstanding83.9960.8970.0179
Slightly volatile
EV To Operating Cash Flow26.3614.1327.5803
Pretty Stable
Intangibles To Total Assets0.590.570.5123
Slightly volatile
Current Ratio1.11.161.486
Slightly volatile
Receivables Turnover3.555.694.4379
Slightly volatile
Graham Number2.7 K2.3 KK
Pretty Stable
Shareholders Equity Per Share2.2 KK3.2 K
Slightly volatile
Debt To Equity0.690.660.6243
Slightly volatile
Capex Per Share12011484.4399
Slightly volatile
Revenue Per Share1.4 K2.6 K2.2 K
Slightly volatile
Interest Debt Per Share3.2 KK2.4 K
Slightly volatile
Debt To Assets0.340.320.281
Slightly volatile
Enterprise Value Over EBITDA16.3212.0617.8385
Slightly volatile
Short Term Coverage Ratios1.711.817.9063
Pretty Stable
Operating Cycle191240262
Pretty Stable
Price Book Value Ratio1.11.161.7853
Slightly volatile
Days Of Payables Outstanding83.9960.8970.0179
Slightly volatile
Price To Operating Cash Flows Ratio7.918.3223.4736
Slightly volatile
Operating Profit Margin0.210.160.1274
Slightly volatile
Company Equity Multiplier1.441.852.0626
Pretty Stable
Long Term Debt To Capitalization0.340.330.3092
Slightly volatile
Total Debt To Capitalization0.40.380.3584
Slightly volatile
Return On Capital Employed0.110.06150.0582
Pretty Stable
Debt Equity Ratio0.690.660.6243
Slightly volatile
Ebit Per Revenue0.210.160.1274
Slightly volatile
Quick Ratio0.570.61.1148
Slightly volatile
Dividend Paid And Capex Coverage Ratio2.072.21.6347
Slightly volatile
Cash Ratio0.10.110.4494
Slightly volatile
Cash Conversion Cycle130192194
Pretty Stable
Operating Cash Flow Sales Ratio0.220.240.1823
Slightly volatile
Days Of Inventory Outstanding131188178
Slightly volatile
Days Of Sales Outstanding94.1966.4585.9809
Slightly volatile
Cash Flow Coverage Ratios0.210.220.9912
Slightly volatile
Price To Book Ratio1.11.161.7853
Slightly volatile
Fixed Asset Turnover4.082.682.8752
Slightly volatile
Capital Expenditure Coverage Ratio6.225.514.8354
Slightly volatile
Price Cash Flow Ratio7.918.3223.4736
Slightly volatile
Enterprise Value Multiple16.3212.0617.8385
Slightly volatile
Debt Ratio0.340.320.281
Slightly volatile
Cash Flow To Debt Ratio0.210.220.9912
Slightly volatile
Price Sales Ratio1.661.752.5774
Slightly volatile
Asset Turnover0.440.370.3577
Slightly volatile
Gross Profit Margin0.730.620.6007
Very volatile
Price Fair Value1.11.161.7853
Slightly volatile

Takeda Fundamental Market Drivers

Forward Price Earnings11.8483
Cash And Short Term Investments405.6 B

Takeda Upcoming Events

1st of February 2024
Upcoming Quarterly Report
View
9th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
9th of May 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of March 2023
Last Financial Announcement
View

About Takeda Pharmaceutical Financial Statements

Takeda Pharmaceutical investors utilize fundamental indicators, such as revenue or net income, to predict how Takeda Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue126.4 B120.1 B
Total Revenue5.3 T5.5 T
Cost Of Revenue1.8 T1.9 T
Sales General And Administrative To Revenue 0.32  0.46 
Research And Ddevelopement To Revenue 0.18  0.20 
Capex To Revenue 0.04  0.03 
Revenue Per Share2.6 K1.4 K
Ebit Per Revenue 0.16  0.21 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether Takeda Pharmaceutical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Takeda Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Takeda Pharmaceutical Co Stock. Highlighted below are key reports to facilitate an investment decision about Takeda Pharmaceutical Co Stock:
Check out the analysis of Takeda Pharmaceutical Correlation against competitors.
You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Takeda Pharmaceutical. If investors know Takeda will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Takeda Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
3.302
Dividend Share
198
Earnings Share
0.23
Revenue Per Share
1.4 K
Quarterly Revenue Growth
0.042
The market value of Takeda Pharmaceutical is measured differently than its book value, which is the value of Takeda that is recorded on the company's balance sheet. Investors also form their own opinion of Takeda Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Takeda Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Takeda Pharmaceutical's market value can be influenced by many factors that don't directly affect Takeda Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Takeda Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Takeda Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Takeda Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.